Evidence map›Paper›PMID 36849807›Full record

SynthesisBone marrow transplantation2023

Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis.

N Aghel, M Lui, V Wang, D Khalaf, H Mian, C Hillis, I Walker, B Leber, J H Lipton, M Aljama and 6 more

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Bone marrow transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

N AghelDivision of Cardiology, Cardio-Oncology Program, McMaster University, and Population Health Research Institute Hamilton, Hamilton, ON, Canada. Aghel@hhsc.ca.
M LuiDepartment of Pharmacy, Hamilton Health Sciences, Hamilton, ON, Canada.
V WangFaculty of Health Sciences, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-3541-2334
D KhalafDepartment of Hematology, McMaster University, Hamilton, ON, Canada.
H MianDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
C HillisDepartment of Hematology, McMaster University, Hamilton, ON, Canada.
I WalkerDepartment of Medicine, McMaster University, Hamilton, ON, Canada.ORCID 0000-0003-0430-3837
B LeberDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
J H LiptonDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
M AljamaDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
K LepicDepartment of Hematology, McMaster University, Hamilton, ON, Canada.
T BergDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
A Garcia-HortonDepartment of Oncology, McMaster University, Hamilton, ON, Canada.ORCID 0000-0003-0579-6709
J PetropoulosHealth Sciences Library, McMaster University, Hamilton, ON, Canada.
H MasoomDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
D P LeongDivision of Cardiology, Cardio-Oncology Program, McMaster University, and Population Health Research Institute Hamilton, Hamilton, ON, Canada.
McMaster University · CAPopulation Health Research Institute · CAHamilton Health Sciences · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular diseases are an emerging cause of mortality and morbidity in survivors of hematopoietic stem cell transplantation (HSCT); however, the incidence of cardiovascular events (CVEs) in this population is not well described. This systematic review summarizes the evidence on the incidence of CVEs in HSCT recipients. Medline and Embase were searched from inception to December 2020. Inclusion criteria were cohort studies and phase 3 randomized controlled trials that reported CVEs among adults who underwent HSCT for hematological malignancies. After reviewing 8386 citations, 57 studies were included. The incidence of CVEs at 100 days was 0.19 (95% CI: 0.17-0.21) per 100 person-days after autologous HSCT and 0.06 (95% CI: 0.05-0.07) per 100 person-days after allogeneic HSCT. This higher incidence after autologous HSCT was driven by reports of arrhythmia from one population-based study in patients with multiple myeloma. The incidence of long-term CVEs was 3.98 (95% CI; 3.44-4.63) per 1000 person-years in survivors of autologous HSCT and 3.06 (95% CI; 2.69-3.48) per 1000 person-years in survivors of allogeneic HSCT. CVEs remain an important but under-reported cause of morbidity and mortality in recipients of HSCT. Future studies are required to better understand the incidence and risk factors for CVEs in HSCT recipients.

Indexed as

Cardiovascular DiseasesHematopoietic Stem Cell TransplantationAdultCohort StudiesHumansRisk FactorsTransplantation, Autologous

Identifiers

PMID36849807
OpenAlexW4322397544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.